Although growing evidence points towards the cDC1 subtype as the ideal platform for next-generation DC vaccines due to its central role in tumour immunity and its superior ability to prime CD8+ T cells [99], a better understanding of DC biology and the immunosuppressive mechanisms that drive DC dysfunction remains essential if DC vaccine efficacy is to be augmented. This evidence concerns the gene MPPE1 and neoplasm.